BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.
- Products & Solutions
- FDA IVD
- About Us
- News & Events
- Contact
- Additional Sites
BUHLMANN News
In this “Q3 2020 Edition” we introduce two NEW BUHLMANN Products. The new FDA Exempt, fecal Pancreatic Elastase (fPELA®) turbo assay, as well newly developed Quantum Blue® 3 Reader (QB3). Also watch the IBDoc® video ‘Want to improve care for IBD patients?’ and lastly watch Dr. Arne Roseth’s AMLI presentation “The latest on IBD Care
Continue Reading
BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading
US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Van den Bergh, P.Y.K., et al., 2021: European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of
Continue Reading
US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Herrendorff R et , 2017: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1619386114 DOI: 10.1073/pnas.1619386114
Continue Reading
US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Toscano G et al., 2020; Guillain-Barré Syndrome Associated with SARS-CoV-2 (Letter to the editor); NEJM; April 27, 2020 DOI: 10.1056/NEJMc2009191 Continue Reading Delmont E et
Continue Reading
McCombie A. et al., A non-inferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and Doc® in the care of IBD patients, Inflamm Bowel Dis, 2019 Highlights from this Publication "Remote symptom and fecal calprotectin monitoring is effective and acceptable. It also reduces the need for face-to-face outpatient appointments." Read Citation
Continue Reading
Hejl et al.; Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Practical Laboratory Medicine, 2017 Highlights from this Publication "This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients." Read Citation Health Canada License: 98903 US: Not available for sale in
Continue Reading
Bello C. et al., Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients, Digestive and Liver Disease, 2017 Highlights from this Publication "The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC
Continue Reading
Heida A. et al., Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clin Gastroenterology and Hepatology, 2017 Highlights from this Publication "Measurements of fecal levels of calprotectin made with home-based lateral flow method were in agreement with measurements made by Quantum Blue and ELISA, as long as
Continue Reading
